Dyad raises £7.5m to turn clinical paperwork into data
What's the deal? UK healthcare AI company DyadDealroom has a profile for this one. Try Dealroom → has raised £7.5 million in a Series A led by Sangha CapitalDealroom has a profile for this one. Try Dealroom →, with participation from Bill Tai and Carbide VenturesDealroom has a profile for this one. Try Dealroom →. The round closed in April 2026 and will fund expansion across the NHS and into new markets.
What's the endgame? Dyad tackles a stubborn coordination problem: longform, unstructured clinical data that takes human effort to create and decode. Its AI system, GENIE, converts unstructured clinical documents into structured data that can enter patient records and trigger tasks for agentic systems.
How does it work? In primary care, GENIE powers BetterLetter, Dyad's clinical coding platform, which has processed more than five million clinical documents. Every suggestion is reviewed by a practice team member before it reaches a patient record.
Founded six years ago by Dr Alexander Tayler and Dr Steven Hamblin, Dyad now serves more than 200 GP surgeries. BetterLetter targets the £300 million annual burden of transferring unstructured data between secondary and primary care.
Why now? The company will use the funding to speed its rollout across UK primary care and extend into secondary care and mental health services, both in the NHS and abroad — including the Middle East and US — where referrals and care planning create similar inefficiencies.
"Some of the most important patient information is still trapped in documents that existing systems cannot properly integrate, creating an unnecessary administrative burden for healthcare teams," said Tayler, chief executive officer.
Carolina Casas Forga at Sangha Capital said the company "has demonstrated both the strength of its technology and clear demand within primary care," adding that there is scope to "apply Dyad's technology across the wider healthcare system."
The signal: At £7.5 million, Dyad's raise sits in the 61st percentile for round size — a mid-sized bet on healthcare's oldest bottleneck. It reflects investor appetite for AI that clears administrative drag rather than replacing clinical judgement.
Read more: businesscloud.co.uk
Image credit: Generated with Gemini
